Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients? A randomized trial.
BACKGROUND
Family caregivers of dementia patients are at increased risk of developing depression or anxiety. A multi-component program designed to mobilize support of family networks demonstrated effectiveness in decreasing depressive symptoms in caregivers. However, the impact of an intervention consisting solely of family meetings on depression and anxiety has not yet been evaluated. This study examines the preventive effects of family meetings for primary caregivers of community-dwelling dementia patients.


METHODS
A randomized multicenter trial was conducted among 192 primary caregivers of community dwelling dementia patients. Caregivers did not meet the diagnostic criteria for depressive or anxiety disorder at baseline. Participants were randomized to the family meetings intervention (n = 96) or usual care (n = 96) condition. The intervention consisted of two individual sessions and four family meetings which occurred once every 2 to 3 months for a year. Outcome measures after 12 months were the incidence of a clinical depressive or anxiety disorder and change in depressive and anxiety symptoms (primary outcomes), caregiver burden and quality of life (secondary outcomes). Intention-to-treat as well as per protocol analyses were performed.


RESULTS
A substantial number of caregivers (72/192) developed a depressive or anxiety disorder within 12 months. The intervention was not superior to usual care either in reducing the risk of disorder onset (adjusted IRR 0.98; 95% CI 0.69 to 1.38) or in reducing depressive (randomization-by-time interaction coefficient = -1.40; 95% CI -3.91 to 1.10) or anxiety symptoms (randomization-by-time interaction coefficient = -0.55; 95% CI -1.59 to 0.49). The intervention did not reduce caregiver burden or their health related quality of life.


CONCLUSIONS
This study did not demonstrate preventive effects of family meetings on the mental health of family caregivers. Further research should determine whether this intervention might be more beneficial if provided in a more concentrated dose, when applied for therapeutic purposes or targeted towards subgroups of caregivers.


BACKGROUND
Controlled-Trials.com ISRCTN90163486.
Department of General Practice and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands. k.joling@vumc.nl
Karlijn J
KJ
Joling
Harm W J
HW
van Marwijk
Filip
F
Smit
Henriëtte E
HE
van der Horst
Philip
P
Scheltens
Peter M
PM
van de Ven
Mary S
MS
Mittelman
Hein P J
HP
van Hout
D000368:Aged; D001007:Anxiety / Q000517:prevention & control*; D017028:Caregivers; D003695:Delivery of Health Care; D003704:Dementia / Q000473:pathology*; D003710:Demography; D003863:Depression / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D012944:Social Support; D016896:Treatment Outcome